LUCIUS 卢修斯 吉三代 Sofosbuvir and Velpatasvir丙肝(1-6型)

吉三代

美国FDA批准上市产品,疗效确切

Sofosbuvir and

卢修斯制药(老挝)有限公司出品

Velpatasvir

老挝国家食药监局批准上市
老挝国家药检所检测认证

Compeiin:
Each film-coated tohle

丙肝(1-6型)

LUCIUS

Loriso Ve is a troed-cose comtiracion ot sofosbuvr, a nepotitns

PHARMACEUTICALS

velpatasvir, an HCV NSSA intibitor, and is incicates forse

LuciSoVe

Recamrended doszerin

irj taken ecaliy once da

Sofosbuvir and Velpatasvir

ful prescribing information for soec ifie doeira an delinec hoced

Tablets

FDA批准

*Fec pedetric petients less chan 6 years of age, actminister
*HCV HIV-1cocnfection: For potients with
coindectien, follea the dosast teco

400mg/100mg

cosage recoemendations in the table 1

recigients without cirrtsosis or with congcn daitr for

L2veeks
resomneudntions forriba
Sterage: in adri nlace ant store st 20C to 29C

Rx Only

Keep meditine out of reach of Children Do not ndirimister
PLEASE SEE PACKAGE INSERT

权威认证

ancy and Lactation:
Maufactured and Marketed by
LUCIUS

28 Tablets

Thongmang village, Xaythany district, Vientian
Coptal, Laos
Warning: To be sokd be rebil on nowrta

口碑质量

适应症:

用于治疗患有慢性HCV基因型1、2、3、4、5或6感染的成人和3岁
及以上儿童患者:
1、无肝硬化或有代偿性肝硬化;
2、有失代偿性肝硬化,可与利巴韦林联合使用。
推荐剂量:

1、成人推荐剂量:每日一次,每次一片(400mg索非布韦和100mg
维帕他韦),可与食物同服或单独服用。
2、3岁及以上儿科患者的推荐剂量:基于体重,请参阅完整说明书。